Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag098 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 03.06.2026. Verfasst von Jun Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: R & D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F Hoffmann-La Roche Ltd., Meiji Seika Pharma Co. Ltd, Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Objectives
Nacubactam is a novel non-β-lactam β-lactamase inhibitor being developed to treat serious Gram-negative bacterial infections. We report data from the first clinical study evaluating nacubactam intravenous (more than 1.5 h) administered to adults with presumed/confirmed complicated urinary tract infections (cUTIs), including pyelonephritis. Patients and methods In this non-randomized, open-label study, 20 patients (mean age 51.5 years; 85.0% white; n = 13 females and n = 7 males) received intravenous infusions (more than 1.5 h) of 2 g nacubactam co-administered with 2 g meropenem three times daily (every 8 h) for 3–14 days.
Results
Nacubactam pharmacokinetic (PK) data were similar to those obtained in prior volunteer studies. With one exception (severe nausea), adverse events (AEs) were of mild to moderate intensity, with no new safety signals, severe AEs or death. Fifty per cent had achieved joint microbiological eradication and clinical cure. Exploratory efficacy analyses in eight evaluable patients with confirmed Gram (−) cUTI identified that at follow-up (ITT population), 75.0% had achieved a clinical response of cure and 62.5% had achieved a microbiological response of eradication. Predicted PK/PD indices suggested that all 20 patients would achieve exposure targets for meropenem (minimum inhibitory concentration of 4 mg/L) and nacubactam (8 mg/L).
Conclusions
The consistent PK and safety profiles of nacubactam, and the ability to align the dosing regimen with partner antibiotics, confirm the suitability of nacubactam for further clinical development in patients with Gram-negative infections.
Autor:innen und Institutionen
- R & D Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
- Roche Pharma Research and Early Development, Roche Innovation Centre New York, Little Falls, NJ, USA.
- Global Product Development, Roche Products Limited, Welwyn Garden City, UK.
- Roche Pharma Research and Early Development, Roche Innovation Centre, New York, NY, USA.
ORCID-Profile: Jun Morita
Förderung
- F Hoffmann-La Roche Ltd.
- Meiji Seika Pharma Co. Ltd
- Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority
Zitieren
APA
Morita, J., Ishiwata, K., Matsumoto, S., Kato, S., Attley, G., Patel, K., Rodriguez, I., & Mallalieu, N. (2026). Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag098
Vancouver
Morita J, Ishiwata K, Matsumoto S, Kato S, Attley G, Patel K, et al. Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag098
BibTeX
@article{Morita2026,
author = {Morita, Jun and Ishiwata, Kazuya and Matsumoto, Shogo and Kato, Seiji and Attley, Gemma and Patel, Katie and Rodriguez, Ignacio and Mallalieu, Navita},
title = {Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag098}
}
EUVIMED